RecruitingNot applicableNCT06934343

Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data

This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical guidelines, the goal of this trial is to refine treatment selection among existing therapeutic options, ensuring that care is tailored to individual patient characteristics. Additionally, by generating real-world evidence, these findings will inform the design and implementation of future clinical trials. Importantly, the methodological advancements will establish a pipeline that extends beyond aNSCLC, facilitating the identification of optimal dynamic treatment regimes (DTRs) for other complex diseases.

Checked against the public recordLast updated May 4, 2026 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations1
SponsorUniversity of Utah
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
University of Utah
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria Subjects must meet all of the following eligibility criteria: * Diagnosed with advanced NSCLC between January 1, 2011, and June 30, 2024. * Follow-up available until December 31, 2024, with a minimum potential follow-up period of at least six months. Exclusion Criteria Subjects meeting any of the following criteria at baseline will be excluded: * Fewer than one day of follow-up post-initiation of first-line (1L) therapy. * Presence of a targetable mutation, including ALK, BRAF, EGFR, KRAS, or ROS1. * PD-L1 expression \<50% at baseline (restricted to patients with PD-L1 ≥50%). * First-line treatment limited to immunotherapy or chemoimmunotherapy (excluding other treatment regimens). * Patients receiving second-line (2L) treatment, including those enrolled in a clinical study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Huntsman Cancer Institute at the University of UtahSalt Lake City, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 4, 2026. Always confirm current availability with the study team.

View original record ↗